This project is designed to answer the critical question of whether replacement of a wild type gene using ex vivo gene therapy is necessary and sufficient to correct the abnormal would repair phenotype observed in EB tissues. Skin fragility in EB appears to derive from heritable defects in EB candidate genes coding for structural components of the basement membrane zone. Since the majority of these BMZ components have only recently been discovered it is unclear how their absence or dysfunction affects would healing and matrix remodeling in the skin. We hypothesize that mutant EB candidate gene products are proteolyticlaly unstable and when expressed their degradation products serve to includence the balance of connective tissue synthesis and degradation via soluble and solid state factors which have yet to be defined. Our preliminary studies support these ideas. We propose to systematically analyze EB skin for the presence and location of matrix metalloproteinases, serine proteinases, inhibitors and matrix products known to modulate tissue remodeling. The results of this work will be used in experiments designed to compare the proteolytic stability of native EB candidate gene products with mutant products produced by EB cells and engineered by recombinant DNA technology. The effects of modulating protolytic activities with inhibitors and antisense constructs will aid in the design of our gene therapy protocols. Finally, we utilize the EB cell lines that we have produced to test the effects of wild type candidate gene replacement on matrix metabolism in defined and novel dual cellular reaction system. In this way, we will elucidate the mechanisms responsible for the cellular """"""""wound remodeling"""""""" phenotype exhibited by EB-derived skin cells.

Project Start
1997-09-30
Project End
1998-06-30
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Stanford University
Department
Type
DUNS #
800771545
City
Stanford
State
CA
Country
United States
Zip Code
94305
Vijayakumar, Soundarapandian; Dang, Suparna; Marinkovich, M Peter et al. (2014) Aberrant expression of laminin-332 promotes cell proliferation and cyst growth in ARPKD. Am J Physiol Renal Physiol 306:F640-54
Tran, Mark; Rousselle, Patricia; Nokelainen, Pasi et al. (2008) Targeting a tumor-specific laminin domain critical for human carcinogenesis. Cancer Res 68:2885-94
Gao, Jing; DeRouen, Mindy C; Chen, Chih-Hsin et al. (2008) Laminin-511 is an epithelial message promoting dermal papilla development and function during early hair morphogenesis. Genes Dev 22:2111-24
Waterman, Elizabeth A; Sakai, Noriyasu; Nguyen, Ngon T et al. (2007) A laminin-collagen complex drives human epidermal carcinogenesis through phosphoinositol-3-kinase activation. Cancer Res 67:4264-70
Pullar, Christine E; Baier, Brian S; Kariya, Yoshinobu et al. (2006) beta4 integrin and epidermal growth factor coordinately regulate electric field-mediated directional migration via Rac1. Mol Biol Cell 17:4925-35
Li, Jie; Zhou, Lisa; Tran, Hoang T et al. (2006) Overexpression of laminin-8 in human dermal microvascular endothelial cells promotes angiogenesis-related functions. J Invest Dermatol 126:432-40
Gonzalez-Quevedo, Rosa; Shoffer, Marina; Horng, Lily et al. (2005) Receptor tyrosine phosphatase-dependent cytoskeletal remodeling by the hedgehog-responsive gene MIM/BEG4. J Cell Biol 168:453-63
Yant, Stephen R; Wu, Xiaolin; Huang, Yong et al. (2005) High-resolution genome-wide mapping of transposon integration in mammals. Mol Cell Biol 25:2085-94
Ortiz-Urda, Susana; Garcia, John; Green, Cheryl L et al. (2005) Type VII collagen is required for Ras-driven human epidermal tumorigenesis. Science 307:1773-6
Arbiser, Jack L; Fan, Chun-Yang; Su, Xiaobo et al. (2004) Involvement of p53 and p16 tumor suppressor genes in recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. J Invest Dermatol 123:788-90

Showing the most recent 10 out of 58 publications